DNA Methylation and Type 2 Diabetes: Novel Biomarkers for Risk Assessment?

Diabetes is a severe threat to global health. Almost 500 million people live with diabetes worldwide. Most of them have type 2 diabetes (T2D). T2D patients are at risk of developing severe and life-threatening complications, leading to an increased need for medical care and reduced quality of life....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gregory Alexander Raciti, Antonella Desiderio, Michele Longo, Alessia Leone, Federica Zatterale, Immacolata Prevenzano, Claudia Miele, Raffaele Napoli, Francesco Beguinot
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	biomarkers DNA methylation type 2 diabetes epigenetics clinical practice Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/44ffaf44ff6c44d39c478c553de76b9c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:44ffaf44ff6c44d39c478c553de76b9c
record_format	dspace
spelling	oai:doaj.org-article:44ffaf44ff6c44d39c478c553de76b9c2021-11-11T17:07:20ZDNA Methylation and Type 2 Diabetes: Novel Biomarkers for Risk Assessment?10.3390/ijms2221116521422-00671661-6596https://doaj.org/article/44ffaf44ff6c44d39c478c553de76b9c2021-10-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/21/11652https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Diabetes is a severe threat to global health. Almost 500 million people live with diabetes worldwide. Most of them have type 2 diabetes (T2D). T2D patients are at risk of developing severe and life-threatening complications, leading to an increased need for medical care and reduced quality of life. Improved care for people with T2D is essential. Actions aiming at identifying undiagnosed diabetes and at preventing diabetes in those at high risk are needed as well. To this end, biomarker discovery and validation of risk assessment for T2D are critical. Alterations of DNA methylation have recently helped to better understand T2D pathophysiology by explaining differences among endophenotypes of diabetic patients in tissues. Recent evidence further suggests that variations of DNA methylation might contribute to the risk of T2D even more significantly than genetic variability and might represent a valuable tool to predict T2D risk. In this review, we focus on recent information on the contribution of DNA methylation to the risk and the pathogenesis of T2D. We discuss the limitations of these studies and provide evidence supporting the potential for clinical application of DNA methylation marks to predict the risk and progression of T2D.Gregory Alexander RacitiAntonella DesiderioMichele LongoAlessia LeoneFederica ZatteraleImmacolata PrevenzanoClaudia MieleRaffaele NapoliFrancesco BeguinotMDPI AGarticlebiomarkersDNA methylationtype 2 diabetesepigeneticsclinical practiceBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 11652, p 11652 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	biomarkers DNA methylation type 2 diabetes epigenetics clinical practice Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	biomarkers DNA methylation type 2 diabetes epigenetics clinical practice Biology (General) QH301-705.5 Chemistry QD1-999 Gregory Alexander Raciti Antonella Desiderio Michele Longo Alessia Leone Federica Zatterale Immacolata Prevenzano Claudia Miele Raffaele Napoli Francesco Beguinot DNA Methylation and Type 2 Diabetes: Novel Biomarkers for Risk Assessment?
description	Diabetes is a severe threat to global health. Almost 500 million people live with diabetes worldwide. Most of them have type 2 diabetes (T2D). T2D patients are at risk of developing severe and life-threatening complications, leading to an increased need for medical care and reduced quality of life. Improved care for people with T2D is essential. Actions aiming at identifying undiagnosed diabetes and at preventing diabetes in those at high risk are needed as well. To this end, biomarker discovery and validation of risk assessment for T2D are critical. Alterations of DNA methylation have recently helped to better understand T2D pathophysiology by explaining differences among endophenotypes of diabetic patients in tissues. Recent evidence further suggests that variations of DNA methylation might contribute to the risk of T2D even more significantly than genetic variability and might represent a valuable tool to predict T2D risk. In this review, we focus on recent information on the contribution of DNA methylation to the risk and the pathogenesis of T2D. We discuss the limitations of these studies and provide evidence supporting the potential for clinical application of DNA methylation marks to predict the risk and progression of T2D.
format	article
author	Gregory Alexander Raciti Antonella Desiderio Michele Longo Alessia Leone Federica Zatterale Immacolata Prevenzano Claudia Miele Raffaele Napoli Francesco Beguinot
author_facet	Gregory Alexander Raciti Antonella Desiderio Michele Longo Alessia Leone Federica Zatterale Immacolata Prevenzano Claudia Miele Raffaele Napoli Francesco Beguinot
author_sort	Gregory Alexander Raciti
title	DNA Methylation and Type 2 Diabetes: Novel Biomarkers for Risk Assessment?
title_short	DNA Methylation and Type 2 Diabetes: Novel Biomarkers for Risk Assessment?
title_full	DNA Methylation and Type 2 Diabetes: Novel Biomarkers for Risk Assessment?
title_fullStr	DNA Methylation and Type 2 Diabetes: Novel Biomarkers for Risk Assessment?
title_full_unstemmed	DNA Methylation and Type 2 Diabetes: Novel Biomarkers for Risk Assessment?
title_sort	dna methylation and type 2 diabetes: novel biomarkers for risk assessment?
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/44ffaf44ff6c44d39c478c553de76b9c
work_keys_str_mv	AT gregoryalexanderraciti dnamethylationandtype2diabetesnovelbiomarkersforriskassessment AT antonelladesiderio dnamethylationandtype2diabetesnovelbiomarkersforriskassessment AT michelelongo dnamethylationandtype2diabetesnovelbiomarkersforriskassessment AT alessialeone dnamethylationandtype2diabetesnovelbiomarkersforriskassessment AT federicazatterale dnamethylationandtype2diabetesnovelbiomarkersforriskassessment AT immacolataprevenzano dnamethylationandtype2diabetesnovelbiomarkersforriskassessment AT claudiamiele dnamethylationandtype2diabetesnovelbiomarkersforriskassessment AT raffaelenapoli dnamethylationandtype2diabetesnovelbiomarkersforriskassessment AT francescobeguinot dnamethylationandtype2diabetesnovelbiomarkersforriskassessment
_version_	1718432173840662528

DNA Methylation and Type 2 Diabetes: Novel Biomarkers for Risk Assessment?

Ejemplares similares